# Sermorelin: The Shortest Active Fragment of GHRH > Sermorelin: Research Overview — Peptide Pros USA — A briefing on sermorelin, the GHRH(1-29) fragment previously approved as Geref: mechanism, the sleep-GH connection, trial findings, and cited safety cautions. **01 / GROWTH HORMONE AXIS RESEARCH** A once-approved growth hormone-releasing hormone analog, read here through the lens of nocturnal GH pulses and slow-wave sleep. ## The short version Sermorelin is a lab-made copy of the first 29 amino acids of the body's own growth hormone-releasing hormone (GHRH) — the shortest piece of that hormone that still fully activates its receptor. It tells the pituitary gland to release the body's own growth hormone (GH) in a pulse, rather than supplying GH directly. It was FDA-approved for pediatric growth hormone deficiency under the brand Geref and pulled from the market in 2008 for business reasons, not for a safety problem. In research-use communities, sermorelin's most consistently reported effect by far is better sleep — falling asleep faster, sleeping more deeply, and reporting vivid dreams, usually within the first couple of weeks. That fits the underlying biology, since the body's largest natural GH pulses happen during deep, slow-wave sleep. But community reports are anecdotal, not clinical evidence, and this page draws a firm line between what a trial measured and what a forum thread describes. ## What it is Sermorelin acetate corresponds to GHRH(1-29) — the amino-terminal 29-residue fragment of the 44-amino-acid hormone the hypothalamus naturally secretes. It is amidated at the C-terminus, a modification that stabilizes the fragment without reducing its potency at the GHRH receptor. Synonyms in the literature include GRF(1-29) and GRF(1-29)NH2. Sermorelin's regulatory history is unusual for a compound now sold as a research peptide: it holds a genuine FDA approval (NDA 020443, marketed as Geref), and it is currently treated as a long-standing Category 1 bulk drug substance under FDA's interim Section 503A compounding policy, finalized January 2025 — a materially different footing than compounds like ipamorelin that were reviewed and restricted at the October 2024 Pharmacy Compounding Advisory Committee meeting. ## How it works Sermorelin binds GHRH receptors on anterior-pituitary somatotrophs, activating the adenylate cyclase/cAMP/PKA signaling pathway to stimulate synthesis and pulsatile release of GH. Because it acts one step upstream of GH itself, the body's own feedback loop — through somatostatin and circulating IGF-1 — stays intact, which is the basis for the argument that sermorelin preserves a more physiologic pattern of GH secretion than injecting recombinant GH directly [4]. ## What the research shows A 2025 review in *Nature Reviews Endocrinology* synthesizes GHRH-receptor biology and the therapeutic and investigational landscape for GHRH analogs, including sermorelin, across health and disease [1]. A placebo-controlled trial of 152 older adults (66 with mild cognitive impairment) gave a related GHRH analog, tesamorelin, at 1 mg subcutaneously each night before bed for 20 weeks. It found a favorable effect on cognition (P=0.03), raised IGF-1 by 117% within the normal physiologic range, and reduced body fat by 7.4%, with adverse events described as mild [2]. That result concerns tesamorelin specifically, but it is the closest controlled human data to sermorelin's own mechanism and nightly dosing pattern. In a multicenter trial of prepubertal children with growth hormone deficiency, once-daily subcutaneous GHRH(1-29) accelerated linear growth, raising first-year height velocity from roughly 4.1 cm/year at baseline to about 7 to 8 cm/year, without generating excessive IGF-1 [5]. In 30 healthy men given intravenous GHRH(1-29)NH2, doses as low as 0.25 mcg/kg produced a significant GH release, with maximal release around 1 to 2 mcg/kg; GH stayed elevated for roughly 3 hours despite rapid plasma clearance, and intranasal bioavailability of the peptide was only about 3 to 5% [6]. In healthy older men (mean age 68), twice-daily subcutaneous GHRH(1-29) for 14 days produced dose-related increases in 24-hour GH and IGF-1, and at the higher dose those levels no longer differed from those of young men, with no change in fasting glucose [7]. Against that trial evidence sits an explicit caution: an *Annals of Internal Medicine* editorial concluded that using growth hormone secretagogues to prevent or treat the effects of aging is "not yet ready for prime time" [3]. ## Reported effects, cautions & safety *The following community-reported effects are anecdotal, not clinical evidence, and no dose is implied by any of them.* Deeper, more restful sleep and vivid dreams are, by a wide margin, the most-mentioned reason people in research-use and telehealth communities say they try sermorelin — often noticed within the first couple of weeks. Many also describe more steady daytime energy and faster exercise recovery, and a slower, gradual loss of body fat (especially around the midsection) over several months, though results vary a great deal by diet, exercise, and consistency. A recurring theme in community write-ups is that sermorelin is a "slow burn" — the first month can feel like nothing is happening, with sleep and energy improvements often not showing up until the second or third month. On the adverse side, mild injection-site redness, itching, or swelling is the most commonly mentioned complaint, usually fading within a couple of hours. Short-lived headache, flushing, dizziness, or nausea are frequently described in the first week or two. Less commonly, users mention water retention or puffiness, increased appetite, next-morning grogginess after a bedtime dose, and — rarely — tingling in the hands or, in people already prone to it, a modest rise in blood sugar. On the cited literature: a formal review found no evidence to justify using GH secretagogues to slow or reverse aging [3]. Separately, because growth hormone and IGF-1 can promote cell growth, deliberately raising them over a long period carries a theoretical, mechanism-based cancer concern common to any GH-axis intervention [1] — sermorelin's feedback-regulated, pulsatile release may temper how high IGF-1 climbs relative to constant GH exposure, but this has not been resolved by long-term human data. Beyond those two points, the wider caution list — glucose effects in older or susceptible people, injection-site and mild metabolic shifts, small off-target hormone changes, blunted response under continuous rather than pulsed dosing, gray-market product-quality concerns, and the sport anti-doping ban — is grounded in the broader GHRH literature and mechanism rather than in sermorelin-specific controlled data, and is reported here as caution, not as a documented sermorelin adverse-event rate. ## Where it fits in the Growth Hormone Axis Sermorelin is the physiologic anchor of this desk — the actual GHRH(1-29) sequence, once an approved drug, and the compound the other three are read against. [CJC-1295](/cjc-1295) engineers that same GHRH-receptor mechanism for a multi-day rather than hours-long pulse. [Ipamorelin](/ipamorelin) reaches the same pituitary cells through an entirely separate receptor. The [CJC-1295/ipamorelin](/cjc1295-ipamorelin) combination pairs sermorelin's own receptor pathway, in its long-acting CJC-1295 form, with ipamorelin's independent one. See the [comparison page](/compare) for all four side by side. --- A clinician's-briefing read of the Growth Hormone Axis literature — findings and citations, never a protocol.